Effects of ranolazine on cardiovascular system

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 215-221

  Bonadei, Ivano ^a   Vizzardi, Enrico ^a   Quinzani, Filippo ^a   Piovanelli, Barbara ^a   Rovetta, Riccardo ^a   D'Aloia, Antonio ^a   Cas, Livio D ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angina pectoris; Atrial fibrillation; Coronary disease; Ranolazine

Indexed keywords

AMIODARONE; AMLODIPINE; ATENOLOL; CARDIAC GLYCOSIDE; DILTIAZEM; ENALAPRIL; ION CHANNEL; METOPROLOL; PLACEBO; RANOLAZINE;

ACUTE CORONARY SYNDROME; ARTICLE; ASTHENIA; BLOOD PRESSURE; CAPILLARY DENSITY; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE EXACERBATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY ACID METABOLISM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART DEATH; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; INSULIN BLOOD LEVEL; INTERMITTENT CLAUDICATION; LONG QT SYNDROME; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATENT; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINUS RHYTHM; STABLE ANGINA PECTORIS; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

EID: 80053550196     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797377103     Document Type: Article

References (55)

1. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for the management of patients with chronic stable angina). J Am Coll Cardiol 2003; 41(1):159-68.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006; 113: e85-e151.
3. Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, et al. Angina 1 year after percutaneous coronary intervention: A report from the NHLBI dynamic registry. Am Heart J 2002; 144:826-833.
4. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, et al. For the arterial revascularization therapies study group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24.
5. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: A multicenter randomized trial. JAMA 1997; 277: 715-721.
6. + regulation in cardiac myocytes. Cardiovasc Res 2003; 57: 897-912.
7. Murphy E, Cross H, Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res 1999; 84: 1469-1470.
8. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/ persistent) sodium current: A potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004; 6(Suppl I): 13-17.
9. Vadnais DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag 2010; 6: 517-530.
10. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93(1): 135-142.
11. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93(3): e26-e32.
12. Belardinelli L, Shyrock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J Suppl 2006; 8 (Suppl): A10-A13.
13. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007; 321: 213-220.
14. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110(8): 904-910.
15. Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol 2010; 56(12): 934-942.
16. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311-336.
17. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43(8): 1375-1382.
18. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA 2004; 291: 309-316.
19. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. ERICA investigators. Antianginal effects of ranolazine when added to treatment with amlodipine: the ERICA (Efficiency of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48: 566-75.
20. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. MERLIN-TIMI Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLINTIMI 36 randomized trial. JAMA 2007; 297: 1775-83.
21. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska- Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina: Observations from the randomized, doubleblind, placebo-controlled MERLIN-TIMI (metabolic efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 trial. J Am Coll Cardiol 2009; 53: 1510-6.
22. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008; 294:H2031-H2209.
23. Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, Verrier RL. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol 2008; 19: 1073-1079.
24. Kloner RA, Dow JS, Bhandari A. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: Through a mechanism favoring inhibition of late sodium channel. Cardiovasc Ther 2010.
25. Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemiareperfusion. Am J Physiol Heart Circ Physiol 2009; 297(5): H1923-H1929.
26. Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol 2009; 42(6): 543-548.
27. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007; 116(13): 1449-1457.
28. Murkock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009; 9: 260-267
29. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008; 8: 175-181.
30. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther. 2004; 9(Suppl 1): S65-S83.
31. Maltsev VA, Sabbah HN, Undrovinas AI. Late sodium current is a novel target for amiodarone: Studies in failing human myocardium. J Mol Cell Cardiol 2001; 33: 923.
32. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long QT syndrome. J Cardiovasc Electrophysiol 2008; 19: 1289-1293.
33. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome- thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-1652.
34. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, et al. Increased late sodium current in myocytes from a canine heart failure and from failing human heart. J Mol Cell Cardiol 2005; 38:475-483.
35. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of druginduced torsade de pointes. Trends Pharmacol Sci 2003;24:619-612
36. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability. Eur J Heart Fail 2007; 9: 219-227.
37. Undrovinas NA, Maltsev VA, Belardinelli L, Sabbah HN, Undrovinas A. Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci 2010; 60(4): 245-2457.
38. Wu Y, Song Y, Belardinelli L, Shryock JC. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-Lcarnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther 2009; 330(2): 550-7.
39. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006; 318(1): 214-222.
40. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006; 92 (Suppl 4): iv6-iv14.
41. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110(8): 894-896.
42. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8(6): 416-422.
43. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008; 295(5): H2149-H2155.
44. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 8: 741-747.
45. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008; 45(1): 32-43.
46. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007; 49: 1027-1034.
47. Belardinelli, L., Antzelevitch, C., Blackburn, B. Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias. EP2198866 (2010)
48. Belardinelli, L., Antzelevitch, C., Blackburn, B. Use of ranolazine for the preparation of a medicament for the treatment of early afterdepolarisations (EADs). EP1930007 (2010)
49. Antzelevich, C., Burashnikov, A., Shryock, J., Rajamani, S., Belardinelli, L. Method of treating atrial fibrillation. WO2010028173 (2010)
50. Lange, L., Jerling, M., Wolff, A. Use of ranolazine for the treatment of cardiovascular diseases. US20100035890 (2010)
51. Lange, L., Jerling, M., Wolff, A. Use of Ranolazine for the treatment of cardiovascular diseases. EP2216024 (2010)
52. Dhalla, A., Belardinelli, L., Shryock, J., Leung, K., Zeng, D. Method for enhancing insulin secretion. US20100105695 (2010)
53. Belardinelli, L., Hoyer, K., Shryock, J. Co-administration of ranolazine and cardiac glycoside. WO2010068461 (2010)
54. Harbeson, S.L, Masse, C. Anti-anginal compounds. US7943620 (2008).
55. Dudley, S. Methods of treating diastolic dysfunction and related conditions. WO2011032099 (2011)